BioNexus Gene Lab Total Revenue

The latest total revenue for BGLC is $3.1M as of June 2026. That compares with $9.6M in the prior-year period — down 67.3% year over year. That is below the sector sector average of $1.4B. Investors often review this figure alongside BioNexus Gene Lab's historical trend and sector peers before judging valuation or financial health.

Over the past year, BGLC's total revenue moved from $9.6M to $3.1M — a 67.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioNexus Gene Lab's operating scale or balance-sheet position.

Against its sector companies, BGLC currently prints $3.1M for total revenue, while the sector average sits near $1.4B. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at BioNexus Gene Lab's growth, margins, and balance sheet.

A total revenue figure of $3.1M for BGLC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $1.4B. Explore the charts below for those layers of context.

After noting BGLC's total revenue ($3.1M), review year-over-year change from $9.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.